Human Immunodeficiency Virus Infection A Modern Day Epidemic
|
|
- Christopher Neal
- 5 years ago
- Views:
Transcription
1 Human Immunodeficiency Virus Infection A Modern Day Epidemic Frank Romanelli, PharmD, MPH, BCPS Assistant Dean and Associate Professor of Pharmacy Clinical Specialist in HIV/AIDS University of Kentucky Learning Objectives Formulate a pharmacologic treatment plan based on patient specific laboratory and psychosocial parameters. Describe advances in the treatment of HIV disease. List available antiretrovirals for the management of HIV disease. 1
2 HIV Positive (HIV +) High risk patient sent for testing Patient s tests are ELISA positive ELISA test is repeated and is positive Test is confirmed by western blot Patient is now said to be HIV positive Acquired Immunodeficiency Syndrome (AIDS) Patients have AIDS when: They are HIV+ with a CD4 cell count that is or ever has been less than 200 cells/mm 3 They are HIV+ and have had an AIDS defining illness such as PCP, toxoplasmosis, MAC, Kaposi s Sarcoma, etc. - regardless of CD4 cell count 2
3 Definitive etiology remains a mystery Multiple theories have been proposed: - sperm overload - antigenicity - advanced tech - genocide/biologic gi warfare - rare chimp likely source of human HIV Etiology Zoonosis Historical Perspective Early 1980s First clinical cases of HIV reported in the US [GRID]. CDC notes increased requests for pentamidine GRID re-named AIDS NIH Isolates HIV Ryan White banned from classes. 3
4 Historical Perspective 1985 ELISA test approved and marketed FDA approval of AZT heralded as HIV cure Ryan White passes 18 years of age Looped red ribbon becomes Intl symbol of HIV. Historical Perspective 1996 Introduction of the PIs Adherence and marked declines in mortality SA Pres. HIV not the cause of AIDS. New side effects and emphasis on QOL First injectable anti-hiv drug (Fuzeon ) launched - cost : $1,200/month First CLIA-waived HIV screening test (OraQuick ) approved. 4
5 Historical Perspective 2007 CDC: HIV testing is routine. Introduction of two new drug classes. (IIs; co-receptor blockers) 2008 Second Generation NNRTIs The search for new targets 25 + Years of HIV and AIDS Morbidity and Mortality Weekly Report June 5, 1981 PCP in 5 otherwise Healthy PCP in 5 otherwise Healthy Homosexual Males in Los Angeles. 5
6 Transmission Primary route of transmission in the US is through sexual contact Blood Semen/vaginal fluids (including oral sex) Perinatal/breast milk Precautions Safer Sex anal vaginal receptive oral sex Latex condoms Standard d precautions Barrier techniques (dental dams) Abstinence 6
7 Perinatal Precautions Intrauterine - ACTG protocol 076 Begin AZT 100mg PO 5X/day at weeks of gestation IV AZT during labor - load with 2mg/kg then 1mg/kg/h until birth AZT 2mg/kg q6h for the 1st 6 weeks of newborn s life 67.5% reduction in perinatal transmission PREVENTION The simplest and most effective preventative measure remains EDUCATION 7
8 Epidemiology Worldwide (2006) 40 million infected persons 4.9 million new infections in % of infected individuals are female More then 20 million deaths Very serious in African continent particularly Sub-Saharan (30-40% of pregnant women) 75% of infections from heterosexual contact Vertical transmission responsible for 95% of childhood cases 8
9 Epidemiology United States (2006) > 1,000,000 cases of HIV New surveillance methodologies: 56,300 new cases (AA 45% of new infections) 12% decline in AIDS cases reported since 96 17% decline in deaths since % of all cases are females 30% white, 49% AA (disproportionate representation), 18% Hispanic Shift: minorities, women, rural, heterosexuals 9
10 Trends in Annual Rates of Death from Leading Causes of Death Among Persons Years Old, USA, Deaths per 100,000 Popula ation * National Center for Health Statistics National Vital Statistics System *Preliminary 1998 data Unintentional injury Cancer Heart disease Suicide HIV infection Homicide Chronic liver disease Stroke Year Diabetes 10
11 US Transmission, 2006 MSM 53% Heterosexual 31% IDU 12% MSM-IDU 4% 11
12 12
13 13
14 Epidemiology Kentucky (12/2007) AIDS Cases: 201 Low prevalence compared to other states 37 (4.9/100K; national average: 12.7/100K) Cases mainly concentrated in Louisville, Lexington, and Northern Kentucky Male: 84%; Female 15%; 1% Children 65% white; 31% AA, 3% Hispanic Risk factors: MSM (55%), IDU(13%), heterosexual sex (15%), undetermined (10%) Cumulative Kentucky HIV/AIDS Cases as of December 2007 Case Type Number of Cases Cases living with AIDS 2,802 Cases of AIDS living and deceased 4,764 14
15 Who Should Be Tested? One-Quarter of all HIV-infected persons are unaware of their status High risk populations only? Men having sex with men (MSM) Promiscuous sex: hetero- or homosexual Injection drug use (IDU) CDC: A routine component of care 13 to 64 YOA HIV ELISA Initial screening test Highly sensitive but not specific High incidence of false positives Positive tests should be repeated and confirmed by a western blot Negative tests should be repeated in 6 months 15
16 Western Blot Confirmatory test DNA finger printing New Testing Technology OraQuick Advantage HIV-1/2 - CLIA-waived 20 minute fingerstick/oral fluid ELISA test. - Confirmation testing still required. - May capture patients who do not report for initial test results. 16
17 OraQuick Advance HIV-1/2 Obtain fingerstick specimen 17
18 Insert loop into vial and stir Collect oral fluid specimens by swabbing gums with test device. Gloves optional; waste not biohazardous 18
19 Insert device; test develops in 20 minutes Positive HIV-1/2 Reactive Control Positive Negative Read results in minutes 19
20 Antiretrovirals Traditional Model of HIV Inhibition 20
21 New Model of HIV Replication Target-cell membrane Coreceptor gp120 gp41 CD4 CD4-induced gp120 conformational change Viral membrane Coreceptor binding Six-helix bundle formation Extended coiled-coil drives insertion of fusion peptide into target membrane Membrane fusion Therapeutic Arsenal Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Protease Inhibitors (PIs) Nucleotide Reverse Transcriptase Inhibitors Fusion Inhibitors Co-receptor antagonists Integrase Inhibitors 21
22 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Inhibit reverse transcriptase enzyme Plagued with drug resistance and intraclass resistance Multiple newer combination drug products Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Zidovudine AZT (Retrovir ) Marrow suppression Didanosine ddi (Videx EC ) Peripheral neuropathy Stavudine d4t (Zerit ) Peripheral neuropathy Lamivudine 3TC (Epivir ) Headache, Nausea Emtricitabine FTC (Emtriva ) Headache, Nausea Abacavir ABC (Ziagen ) Hypersensitivity Combivir Tii Trizivir i Truvada Epzicom AZT/3TC AZT/3TC/ABC FTC/TF 3TC/ABC 22
23 Atripla Emtricitabine 200 mg + Tenofovir 300 mg + Efavirenz 600 mg First triple therapy single pill option Gold standard? Unprecedented manufacturer cooperation Cost comparable Single co-pay? 1 PO Qhs The Ideal Antiretroviral Potent. Easily administered. Low cost. High resistance barrier. Effective as monotherapy. Few adverse effects. Few drug interactions. Disturb latent HIV reservoirs. 23
24 Nucleotide Reverse Transcriptase Inhibitors Inhibit reverse transcriptase enzyme Requires less intracellular phosphorylation and activation Less amenable to resistance Salvage therapy Nucleotide Reverse Transcriptase Inhibitors Tenofovir (Viread ) 300mg PO QD Efficacy against Hep B Nausea/vomiting 24
25 Non-nucleoside Reverse Transcriptase Inhibitors Structurally distinct i from the NRTIs Resistance remains a problem as does cross-resistance Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine (Viramune ) Rash, Diarrhea Delavirdine (Rescriptor ) Rash, Headache Efavirenz (Sustiva ) Rash, CNS Disengagement 200 mg qd x 2 weeks then 200 mg BID 400 mg TID 600 mg Qhs 25
26 The First Arrival of 2008 Etravirine (Intelence ) Formerly TMC125 Second generation NNRTI Higher resistance ceiling [K103N] [Y181C] 200 mg PO BID Salvage therapy Rash, diarrhea D/I: (several) Tip, famp, ATA Protease Inhibitors Among the most potent of the antiviral medications Resistance develops quickly, especially in cases of non-adherence Wide intra-class resistance Boosting 26
27 Protease Inhibitors Saquinavir (Invirase ) Nausea, vomiting, diarrhea Ritonavir (Norvir ) D/I, GI distress, perioral tingling Indinavir (Crixivan ) Nephrolithiasis, increased bilirubin Nelfinavir (Viracept ) Diarrhea, nausea 500 mg BID 600 mg BID 800 mg q8h 1250 mg BID Protease Inhibitors Lopinavir/Ritonavir (Kaletra ) Nausea, HyperTG, diarrhea Fosamprenavir (Lexiva ) Nausea, diarrhea Atazanavir (Reyataz ) Increased bilirubin 2 Caps BID 700 mg BID (variable) 400 mg QD Tipranavir i (Aptivus ) 500 mg BID (boosted) Nausea, diarrhea Darunavir (Prezista ) Nausea, diarrhea 600 mg BID (boosted) 27
28 Fusion Inhibitors Enfurvitide (Fuzeon ) 90mg SQ BID $$ Injection site reactions Salvage therapy Co-Receptor Antagonists AKA chemokine receptor blockers Block either CCR5 or CXCR4 Concern regarding trophism [CXCR4 associated with increased virulence] Theoretical concerns: malignancy, infection, others? 28
29 Maraviroc (Selzentry ; Celsentri ) Father of the class CCR5 antagnoist Indicated for tx experienced patients only Requires trophic assay before use - $$$ [TroFile TM ] Dose: 150 mg PO BID varies with concurrent drug use [interactions] i Pneumonia? Malignancy? Cardiovascular complications? Trophic conversion? Integrase Inhibitors Raltegravir (Isentress ) Newest anti-hiv class Years of research Tx experienced patients only 400 mg PO BID HA, NV, CPK UGT1A1 Glucuronidation D/Is: Tip/Rit, Rif Cost: $27.00/day ($2.00/d less than MAR) 29
30 Treatment Resistance testing recommended for all patients entering care. All symptomatic patients Asymptomatic patients: CD4 + cell count < 350 cells/mm 3 All patients: Pregnant, HIV-nephropathy, Hep B co-infected (where Hep B tx is indicated) Treatment Regimens Typical backbones: 2 NRTIs + 1 NNRTI 2 NRTIs + 1 PI Initial Regimens: Downgrades: AZT/3TC; D4T/3TC; NFV Upgrades: 3TC/ABC (HLA-B*5701); Saq/rit 30
31 Goal of Therapy Primary Goal To reduce and maintain plasma HIV RNA levels (viral load) below the point of detection <48 COPIES/ML Secondary Goal Preservation of the CD4 + cell count Drug Toxicity or Adverse Effects Doses of drugs should not be decreased in response to an adverse effect or toxicity Clinicians should D/C the drug and substitute another drug from the same class 31
32 Antiretroviral Resistance Testing Technique Advantage Limitation Genotyping Phenotyping - Availability - Days to results - Less technical - Direct measure of susceptibility - More familiar reporting results (IC 50, IC 90 ) - Indirect measure - Expert interpretation required - Minor species not tested -Costly - Weeks to results - More technical - Minor species not detected - Breakpoints undefined 32
33 Opportunistic Infection Prophylaxis and Treatment Pneumocystic jiroveci formerly Pneumocystic carinii (PCP) Prophylaxis (CD4 + cell count <200): Bactrim DS 1 PO QD Treatment: Bactrim IV 15 mg/kg/d x 21 d Toxoplasmosis gondii Prophylaxis (CD4 + cell count <100): Bactrim DS 1 PO QD Treatment: Sulfadiazine and Pyrimethamine Opportunistic Infection Prophylaxis and Treatment Mycobacterium avium Complex Prophyalxis (CD4 + cell count <50): Azithromycin 1200 mg PO Qweek Treatment: Clairithromycin and Ethambutol Candida albicans Prophylaxis (Frequent, recurrent, or severe infection): Fluconazole Treatment: Fluconazole High Dose or IV 33
34 Medication Burden HIV treatment only marginally better than HIV disease itself. Zidovudine I have no energy. Nelfinavir I m having BM per day! Stavudine I need methadone for the pain! PIs Look what has happened to my face! Ritonavir I can t stop throwing up! Atazanavir I m yellow! Efavirenz I m too scared to go to sleep! Indinavir I have a horrible pain in my side! Financial Burden Clinic visits q3 months Consults q12 months Eye, dental Lab Monitoring q3 months CMP, CBC, VL, CD4 + cell count, lipids, LFTs Antiretroviral therapy ~ $1,200/month OI Medications 34
35 Unresolved Issues In patients with long term undetectable viral loads, is it ever possible to D/C medications? Why do certain subsets of patients who have definite exposures to HIV not seroconvert? Are medications the answer? Vaccine Obstacles No approved vaccine to date Can a natural protective state against HIV exist? No human disease model Long term survivors/slow progressors offer best models Lack of animal models also poses a challenge 35
36 Ticking Clock " Let us today set a new national goal for science in the age of biology. Today, let us commit ourselves to developing an AIDS vaccine within the next decade... If America commits to find an AIDS vaccine and we enlist others in our cause, we will do it. I am prepared to do all I can to make it happen. Pres. Bill Clinton, 1997 Lessons Learned 36
37 Historical Perspective 2008 Elvitegravir (Another II) X4 blockers Oral fusion inhibitors Why not start therapy earlier? No novel class ARVs in Phase III trials. 37
38 HIV and AIDS 38
THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationNothing to disclose.
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital HIV UPDATE FOR THE PRIMARY CARE PROVIDER Nothing to disclose. 1 Outline Epidemiology Screening / testing for HIV
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationHIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options
STRATEGIES FOR THIRD LINE HIV THERAPY issues to consider when faced with few drug options A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Most people living
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationWOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM
WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More informationHIV/AIDS Update 2007
HIV/AIDS Update 2007 Joanne J. Orrick, Pharm.D., BCPS Clinical Assistant Professor University of Florida Faculty, Florida/Caribbean AIDS Education and Training Center orricjj@ufl.edu www.faetc.org orricjj@ufl.edu
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationHIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time
STRATEGIES FOR FIRST LINE HIV THERAPY issues to think about when going on therapy for the first time A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Deciding
More informationDrug Treatment Program Update
Drug Treatment Program Update As of March 211 Drug Treatment Program Update A key component of the Centre s mandate is to monitor the impact of HIV/AIDS on British Columbia. The Centre provides essential
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationREIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO
REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO Ont. Drug Distr. Ontario Drug Benefit/Trillium: Other Formulary (F/A) Limited Use (Section 16) Antiretrovirals AZT 100 mg capsules NRTIs (single): Abacavir,
More informationPage 1 of 5 ENLGLISH / ESPAÑOL / PORTUGUÉS / FRANÇAIS Share 3 Drug Chart for HIV Treatment CURRENT EDITION ABOUT SENSE BACK ISSUES MSMGF HOME CONTACT US There are a number of antiretroviral (ARV) medications
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute
ADAP Monitoring Provider Prescribing Patterns Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute WEBINAR ETIQUETTE All questions or comments can be shared either via the
More informationHuman Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More informationGenotyping and Drug Resistance in Clinical Practice. Case Studies
Genotyping and Drug Resistance in Clinical Practice Case Studies 12/02 40 year old Hispanic male Dx with HIV 1995 + Hx of PCP > 1x, HepC Medication history: AZT, Crixivan, Videx EC, Sustiva, Zerit, Ziagen,
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationDaclatasvir (Daklinza ) Drug Interactions with HIV Medications
Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir
More informationSculpting a Better Regimen: The ART of HIV Medications
Sculpting a Better Regimen: The ART of HIV Medications Kelly Peddy, PharmD, MPA Clinical Pharmacy Specialist - Ambulatory Care Memorial Hospital of South Bend November 30, 2017 For HealthTrust Members
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationFluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids
Supportive therapy Summary of interactions Table 1. Summary of potential interactions between antiretroviral agents and supportive therapy Interactions with enzyme inhibitors (protease inhibitors and elvitegravir/cobicistat)
More informationMedscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection
Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Generic Name (Abbreviation) / Trade Name Abacavir (ABC) / Ziagen Trizivir with ZDV + 3TC Epzicom with 3TC Didanosine (ddi)
More informationA Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs
ADDRESSING GAPS IN INNOVATION FOR NEGLECTED PATIENTS: DNDI ANDPEDIATRIC HIV/AIDS Rachel Cohen, Regional Executive Director, DNDi North America Proposals for a Global Innovation System that Responds to
More informationObjectives. HIV Treatment in Recently In 1996 the introduction of protease inhibitors decreasing the death rate of those infected by 50%.
Objectives Identify modes HIV transmission and methods of prevention. HIV Treatment in 2010 Lisa D. Inge, Pharm.D., BCPS, AAHIVE Assistant Director, Jacksonville Campus Clinical Assistant Professor University
More informationALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS
ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS - 2014 Alabama s ADAP formulary offers a minimum of one medication from each HIV antiretroviral class approved by the U.S. Food and Drug Administration (FDA).
More informationOB/GYN CHART REVIEW DRAFT: NOT FOR DISTRTIBUTION
OB/GYN CHART REVIEW A summary of OB/GYN clinical chart review results designed to monitor the quality of care provided by a Ryan White funded OB/GYN primary care site as part of the Atlanta EMA s quality
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationApproach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.
Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D. Disclosures: grant support from Gilead, Roche, EBSCO Objectives Apply current guidelines to initial evaluation
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationOctober 26-28: Training Day 1
Peer Linkage and Re-Engagement of HIV- Positive Women of Color October 26-28: Training Day 1 Peer Linkage and Re -Engagement of HIV - Positive Women of Color Convening Training Trainers Today: Alicia Downes
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationHIV epidemiology since HIV in the United States. HIV Transmission
HIV epidemiology since 1999 8% increase in HIV diagnoses Men who have sex with men (MSM) increased 14% Heterosexual increased 10% IVDU decrease about 30% Young Black MSM 15% incidence HIV in the United
More informationAntiretrovial Crushable/Liquid Formulation Chart
Antiretrovial Crushable/Liquid Formulation Chart Eliza Dollard, PharmD; Nafeesa Chin-Beckford, PharmD; Laura Aragon, PharmD Last Updated: 04/2016 Agent How Supplied Crushable Status **Products listed in
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationOverview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments - Dr. Christina Polyak - Dr. Julie Ake Disclaimer The views expressed in this presentation are
More informationHIV for the Non-ID Pharmacist
Disclosures HIV for the Non-ID Pharmacist I have nothing to disclose at this time Carmen Faulkner-Fennell, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist--Infectious Diseases Greenville Hospital System
More informationHIV and YOU. Special 2008 Update!
HIV and YOU Special 2008 Update! HIV and You Special 2008 Update! In this booklet, you ll see words in bold, red type. Go to the Glossary on the back cover to find out what these words mean. WRITERS AND
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationcontinuing education for pharmacists
continuing education for pharmacists HIV/AIDS: Overview and Resources for Pharmacists Mona T. Thompson, R.Ph., PharmD Volume XXXIII, No. 9 Dr. Mona T. Thompson has no relevant financial relationships to
More informationAIDS 101: From Abstinence to Zidovudine
AIDS 101: From Abstinence to Zidovudine Frank Romanelli 1 College of Pharmacy, University of Kentucky, 800 Rose Street, C11 7, Lexington KY 40536 PROLOGUE Development of the Acquired Immune Deficiency
More informationNON-OCCUPATIONAL POST EXPOSURE PREVENTION. when you think you were exposed to hiv within the past three days
NON-OCCUPATIONAL POST EXPOSURE PREVENTION when you think you were exposed to hiv within the past three days A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY
More informationHIV Clinical Nurse Specialist CCDHB Wellington
RN James Rice-Davies HIV Clinical Nurse Specialist CCDHB Wellington 11:00-11:55 WS #88: Undiagnosed HIV in Your Practice 12:05-13:00 WS #99: Undiagnosed HIV in Your Practice (Repeated) HIV- Undiagnosed
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
More informationOverview of HIV. LTC Paige Waterman
Overview of HIV LTC Paige Waterman Outline Background and Epidemiology HIV Virology, Transmission, and Pathogenesis Acute HIV infection HIV Diagnostics Management of Health Care Personnel Exposed to HIV
More informationTB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
More informationP.I. Perspective. December 2008, Issue #47. Information, Inspiration and Advocacy for People Living with HIV/AIDS
P.I. Perspective December 2008, Issue #47 Information, Inspiration and Advocacy for People Living with HIV/AIDS This issue of PI Perspective represents Project Inform s coverage of the joint 2008 ICAAC
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationTB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
More informationHIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine
HIV Update Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine Rates of Diagnoses of HIV Infection among Adults and Adolescents, 2012 United States and 6 Dependent
More informationYear 2002 Paper two: Questions supplied by Jo 1
Year 2002 Paper two: Questions supplied by Jo 1 Question 9 A 37 year old man with known human immunodeficiency virus (HIV) infection for 10 years presents with severe renal colic for which he has no prior
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationFORMULARY Virginia (VA) AIDS Drug Assistance Program (ADAP) LAST UPDATED: December At a Glance: VA ADAP Formulary
At a Glance: VA ADAP Formulary Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Non Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Multi Class Combination Agents Protease Inhibitors
More informationNATAPNATIONAL. HIV 102: Care & Treatment AIDS TREATMENT ADVOCACY PROJECT. Origins of HIV. Table of Contents. National AIDS Treatment Advocacy Project
National AIDS Treatment Advocacy Project HIV 102: Care & Treatment Written by: Jose Castro, MD University of Miami, Miller School of Medicine, Miami, FL Editorial Contributions by: Jules Levin 580 BROADWAY,
More informationMidwestern Underwriting Conference 2016
UNDERWRITING HIV: THE FAIRY TALE HAS BECOME REALITY Midwestern Underwriting Conference 2016 Jean-Marc Fix, FSA, MAAA VP, R&D, Optimum Re Insurance Co. AGENDA Where are we with HIV? The risk The ideal case
More informationNON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION. Jason E. Vercher, PA-C, AAHIVM
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION Jason E. Vercher, PA-C, AAHIVM Disclosures No disclosures to report Learning Objectives q Identify Individuals who would benefit from non-occupational
More informationHIV Infection & AIDS in Low- and Middle-Income Countries
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 25: HIV Infection & AIDS in Low- and Middle-Income Countries Author P. Van de Perre, MD, PhD Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More informationTerapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos
Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos (Antiretroviral Therapy Present and Future Prospects of Antiretroviral Drugs in Initial and Salvage Therapy)
More informationPHCP 403 by L. K. Sarki
PHCP 403 by L. K. Sarki objectives To gain insight into the epidemiology of HIV To gain basic understanding of the etiology of HIV disease To know the clinical manifestations of the disease To gain a basic
More informationMatters of the HAART: An Update on Current Treatment Options for HIV
Matters of the HAART: An Update on Current Treatment Options for HIV Jason Alegro, PharmD, BCPS Assistant Professor of Clinical Sciences, Roosevelt University Infectious Diseases Clinical Pharmacy Specialist,
More informationHuman Immunodeficiency Virus (HIV)
HIV INFECTION! Human Immunodeficiency Virus (HIV) Infects human cells and causes gradual loss of immune system function, and these immune alterations predispose to the opportunistic infections, neoplasms,
More informationAdherence Strategies for Older Adults. AIDS Community Research Initiative of America (ACRIA)
Adherence Strategies for Older Adults AIDS Community Research Initiative of America (ACRIA) June 2008 Modular Objectives By the end of the module, participants will be able to: Define adherence Be able
More informationHIV Integrase Inhibitors: Current and Future Use. Douglas G. Fish, MD Albany Medical College Cali, Colombia March 13, 2008
HIV Integrase Inhibitors: Current and Future Use Douglas G. Fish, MD Albany Medical College Cali, Colombia March 13, 2008 Which of the following statements about raltegravir is false? a) Raltegravir is
More informationAddressing Pediatric Needs of the Most Neglected: next steps
Addressing Pediatric Needs of the Most Neglected: next steps An updated overview of DNDi Pediatric Focus Nathalie Strub Wourgaft (Medical Director) Janice Lee (HIV Pediatric Clinical Manager) A Fatal Imbalance
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
More informationApproach for the Newly Diagnosed HIV Positive Patient
Approach for the Newly Diagnosed HIV Positive Patient Jason E. Farley, PhD, MPH, ANP-BC, FAAN, AACRN Associate Professor & NP, Johns Hopkins University School of Nursing & Medicine Director, AETC Adult-Gerontology
More informationHIV Treatment Guidelines
HIV Treatment Guidelines Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Are Treatment Guidelines? Issued by variety of global and country-based
More informationNew Frontiers for Treatment Strategies for HIV Care
New Frontiers for Treatment Strategies for HIV Care Eric S. Daar, MD Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Disclosures:
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationBHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search
BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search Search 1 :When to Initiate ART Covers Questions 1-5 including to prevent transmission Component Description Review area Objectives
More informationWorld AIDS Day Year-by-Year Milestones in HIV/AIDS. healthlibrary
World AIDS Day 2014 Year-by-Year Milestones in HIV/AIDS (Adapted from The POZ Timeline: Milestones in the HIV/AIDS Pandemic with additions compiled by Eric Brus, Director of HIV Health Promotion, AIDS
More informationWhen to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
More informationThe ART of Antiretroviral Therapy in Critically-ill Patients with HIV
The ART of Antiretroviral Therapy in Critically-ill Patients with HIV Tyler Finocchio, PharmD, BCPS PGY2 Critical Care Pharmacy Resident Avera McKennan Hospital & University Health Center February 10 th,
More informationtreatment passport 1
treatment passport 1 Why keep a treatment history? Keeping a short record of your treatment history can help in many ways. It can help you understand your health and treatment. It can help if your doctor
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationJULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet
JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationPage 1. Outline. Outline. Building specialized knowledge: HIV. Biological interactions. Social aspects of the epidemic. Programmatic actions
Harvard-Brazil Collaborative Public Health Field Course January 2014 Lecture # 8 Building specialized knowledge: HIV Aluisio Segurado Department of Infectious Diseases School of Medicine, University of
More informationHIV and AIDS An update
HIV and AIDS An update Barnet branch 24 th February 2009 Neal Marshall Specialist pharmacist HIV services Royal Free Hampstead NHS Trust Objectives To gain an insight into the epidemiology of HIV To gain
More informationPrinciples of HIV Drug Resistance: Resistance to New Drug Classes. Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada
Principles of HIV Drug Resistance: Resistance to New Drug Classes Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada Why Is It Important to Understand HIV Drug Resistance? 1. Resistance
More informationHIV and AIDS. Shan Nanji
HIV and AIDS Shan Nanji HIV 2 Description: Enveloped Positive Sense HIV 3 Structural Genes: Cleavage of gp160 leads to formation of ENV: Gp120: attachment to host CD4 T Cell Gp41: GAG (p24) Capsid protein
More informationOutline Epidemiology: Global and U.S. How are we doing in terms of goals of treatment? Updates in the fast moving field of HIV medicine EPIDEMIOLOGY
Updates in the fast moving field of HIV medicine 35 th Advances in Infectious Diseases April 25, 2014 Monica Gandhi MD, MPH Professor of Medicine and Clinic Director ( Ward 86 ), Division of HIV/AIDS San
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2012 EDURANT 25 mg film-coated tablets B/30 (CIP code: 219 472-9) Applicant: JANSSEN-CILAG rilpivirine ATC code
More informationTORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman
More information